Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Nexavar Well Tolerated in Japanese Renal Cancer Patients
July 7, 2008
- REGULATORY NEWS IN BRIEF
July 7, 2008
- PPIs Drugs of Choice for Dyspepsia Symptoms: J-FOCUS Study
July 7, 2008
- DSP Quickly Expands R&D Pipeline in the Field of Diabetes
July 7, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 7, 2008
- MEDICAL DEVICE NEWS IN BRIEF
July 7, 2008
- Bayer Yakuhin to Achieve \200 Bil. Sales in 5 Years
July 7, 2008
- Physician-led Study of Talc to Begin Soon
July 7, 2008
- Daiichi Sankyo to Work Out Collaboration Plans Country by Country: Mr Shoda
July 7, 2008
- Sawai Aims at Achieving \100 Bil. Sales before Any Other Generic Company in Japan
July 7, 2008
- Otsuka Pharm. to Be Reorganized under New Holding Company
July 7, 2008
- Blopress Best-Selling Ethical Drug 4 Years in a Row
July 7, 2008
- Ethical Drugs Market Up to \8,136.3 Bil. in FY2007: IMS Japan
July 7, 2008
- More Attendants, Questions at Major Pharmas' Shareholders' Meetings
July 7, 2008
- R&D NEWS IN BRIEF
July 7, 2008
- BUSINESS NEWS IN BRIEF
July 7, 2008
- 7-Year Strategy for Hepatitis Calls For Radical Cure Rate of 70% for Hepatitis C
July 7, 2008
- English-Speaking Japanese Executives Earn up to 30% More than Non-English Speaking Colleagues: Survey
July 7, 2008
- Generic Anticancer Drugs Used in 16% of Hospitals with 100 or More Beds: Survey
July 7, 2008
- Gov't to Maintain Policy to Cut \1.1 Tril.
July 7, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…